Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769341 | 1.00 | L3MBTL1 (0.53) | L3MBTL1KMT2ALMNAHPGDNFE2L2 | |
| SCHEMBL3772235 | 0.92 | TDP1 (0.43) | L3MBTL1KMT2ALMNAHPGDKDM4E | |
| SCHEMBL3772240 | 0.92 | TDP1 (0.43) | L3MBTL1KMT2ALMNAHPGDKDM4E | |
| SCHEMBL3774586 | 0.92 | HPGD (0.60) | L3MBTL1HPGDNFE2L2KDM4ENPC1 | |
| SCHEMBL3774593 | 0.92 | HPGD (0.60) | L3MBTL1HPGDNFE2L2KDM4ENPC1 | |
| SCHEMBL14190940 | 0.89 | KMT2A (0.61) | L3MBTL1KMT2ALMNAHPGDNFE2L2 | |
| SCHEMBL4382984 | 0.89 | KMT2A (0.61) | L3MBTL1KMT2ALMNAHPGDNFE2L2 | |
| SCHEMBL14190925 | 0.88 | KMT2A (0.60) | L3MBTL1KMT2ALMNAHPGDNFE2L2 | |
| SCHEMBL4386306 | 0.88 | KMT2A (0.60) | L3MBTL1KMT2ALMNAHPGDNFE2L2 | |
| SCHEMBL3765817 | 0.87 | ITGB2 (0.42) | L3MBTL1KMT2ALMNAHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | L3MBTL1 1468/4885KMT2A 242/4885LMNA 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.